Bluefin Acquires TECS to Combine Payments and Data Security Solutions
1.11.2022 16:00:00 CET | Business Wire | Press Release
Bluefin, the recognized integrated payments leader in PCI-validated encryption and tokenization technologies that protect payments and sensitive data, today announced the acquisition of TECS Payment Systems, a global provider of omnichannel payment solutions to acquirers, payment service providers and POS system providers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221101005043/en/
Consumer demand for omnichannel payment options has grown at an astounding rate. According to Insider Intelligence, e-commerce sales are expected to reach$6.169 trillionin 2023, up from $3.351 trillionin 2019, while mobile payments are projected to grow from $1.97 trillion in 2021 to $11.83 trillion in 2028, reports Fortune Business Insights. Merchants require payment acceptance and processing technologies—whether in-person contactless, digital wallet, mobile or online—that ensure data privacy and security.
Together, Bluefin and TECS will serve 34,000 connected merchants and nearly 300 global partners in 55 countries. The strategic combination expands the global footprint of both organizations. Bluefin and its customers gain omnichannel payments and smartPOS capabilities that will integrate with the company’s existing payments and data security suite. TECS and its customers will benefit from the addition of data security solutions that address growing needs of larger organizations, as well as additional resource investment in the innovative TECS product and solution suite.
“We are delighted to welcome TECS’ employees, customers and partners to Bluefin,” said John M. Perry, CEO, Bluefin. “This combination brings together two companies that focus relentlessly on meeting merchant needs for next-generation payment processing and management as well as the secure exchange of PHI and PII data with PCI-validated encryption and tokenization.”
The TECS platform supports international card payments, fleet cards, account-based payments and digital wallets processed through in-person, mobile, unattended and e-commerce channels. SmartPOS devices are offered from Sunmi and Newland through the company’s own AppStore and Terminal Management Systems (TMS). Gateway features include multi-currency processing, a robust fraud system, a gift card/loyalty program and a proprietary 3D Secure (3DS) solution integrated with the card brands.
Bluefin specializes in encrypted and tokenized integrated payments through their PCI-validated point-to-point encryption (P2PE) solutions for point-of-sale (POS) transactions and ShieldConex® data security platform for the tokenization of payments, Personally Identifiable Information (PII) and Protected Health Information (PHI) entered online.
“There were natural synergies between the TECS and Bluefin solutions and teams,” said Fazlollah Rostamian, Founder & CEO, TECS. “We are excited about what the strength of our combined resources will mean for our customers, and the many ways we can help businesses provide the payment experience that their customers demand.”
TECS will be integrated into the Bluefin team and continue its Austria-based operations, managed locally by TECS CEO and founder Fazlollah Rostamian.
About Bluefin
Bluefin is the recognized integrated payments leader in encryption and tokenization technologies to protect payments and sensitive data. Bluefin’s product suite includes solutions for contactless face-to-face, call center, mobile, Ecommerce and unattended payments and data in the healthcare, higher education, government and non-profit industries. The company’s 200 global partners serve 20,000 enterprise and software clients operating in 47 countries. For more information, visit https://www.bluefin.com/.
About TECS
Founded in 2000, TECS provides omnichannel payment solutions to Acquirers, Payment Service Providers, POS system providers, Independent Software Vendors and other merchant aggregators around the globe based on an open cloud-based payments platform. The TECS payments platform is integrated with over 100 technology partners, acquirers, processors and payment providers worldwide, including Fiserv, Global Payments, Worldline, EVO Payments and more, and connects 14,000 merchants in 17 countries with their in-store, unattended, mobile, and e-commerce solutions. For more information, visit https://www.tecs.at/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221101005043/en/
Contact information
Danielle Duclos
Senior Vice President, Marketing
Bluefin
800-675-6573
press@bluefin.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press Release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press Release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press Release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom